Cargando…

A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans

INTRODUCTION: Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of oral malignancies and has a 5-year mortality rate close to 50%. A consistent part (70%) of all oral cancers is diagnosed at an advanced stage since available screening techniques are ineffective. Therefore, it would...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebaudi, Federico, De Rosa, Alfredo, Greppi, Marco, Pistilli, Roberto, Pucci, Resi, Govoni, Flavio Andrea, Iacoviello, Paolo, Broccolo, Francesco, Tomasello, Giuseppe, Pesce, Silvia, Laganà, Francesco, Bianchi, Bernardo, Di Gaudio, Francesca, Rebaudi, Alberto, Marcenaro, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358763/
https://www.ncbi.nlm.nih.gov/pubmed/37483588
http://dx.doi.org/10.3389/fimmu.2023.1216107
_version_ 1785075735127392256
author Rebaudi, Federico
De Rosa, Alfredo
Greppi, Marco
Pistilli, Roberto
Pucci, Resi
Govoni, Flavio Andrea
Iacoviello, Paolo
Broccolo, Francesco
Tomasello, Giuseppe
Pesce, Silvia
Laganà, Francesco
Bianchi, Bernardo
Di Gaudio, Francesca
Rebaudi, Alberto
Marcenaro, Emanuela
author_facet Rebaudi, Federico
De Rosa, Alfredo
Greppi, Marco
Pistilli, Roberto
Pucci, Resi
Govoni, Flavio Andrea
Iacoviello, Paolo
Broccolo, Francesco
Tomasello, Giuseppe
Pesce, Silvia
Laganà, Francesco
Bianchi, Bernardo
Di Gaudio, Francesca
Rebaudi, Alberto
Marcenaro, Emanuela
author_sort Rebaudi, Federico
collection PubMed
description INTRODUCTION: Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of oral malignancies and has a 5-year mortality rate close to 50%. A consistent part (70%) of all oral cancers is diagnosed at an advanced stage since available screening techniques are ineffective. Therefore, it would be urgent to improve them. The diagnostic gold standard is tissue biopsy with histological and immunohistochemical assessment. This method presents some limitations. Biopsy is invasive and the histopathological evaluation is semi-quantitative, and the absolute abundance of the target cannot be reliably determined. In addition, tissue is highly processed and may lead to loss of information of the natural state. The search for classical and new clinical biomarkers on fragments of tissue/cells collected with a cytobrush is a highly hopeful technique for early detection and diagnosis of OSCC, because of its non-invasive sampling and easy collection method. METHODS: Here we analyzed cytobrush biopsies samples collected from the oral cavity of 15 patients with already diagnosed OSCC by applying an innovative high-sensitivity ELISA technique, in order to verify if this approach may provide useful information for detection, diagnosis, and prognosis of OSCC. To this end, we selected six biomarkers, already used in clinical practice for the diagnosis of OSCC (EGFR, Ki67, p53) or selected based on recent scientific and clinical data which indicate their presence or over-expression in cells undergoing transformation and their role as possible molecular targets in immunecheckpoints blockade therapies (PD-L1, HLA-E, B7-H6). RESULTS: The selected tumor biomarkers were highly expressed in the tumor core, while were virtually negative in healthy tissue collected from the same patients. These differences were highly statistically significant and consistent with those obtained using the gold standard test clearly indicating that the proposed approach, i.e. analysis of biomarkers by a custom ELISA technique, is strongly reliable. DISCUSSION: These preliminary data suggest that this non-invasive rapid phenotyping technique could be useful as a screening tool for phenotyping oral lesions and support clinical practice by precise indications on the characteristics of the lesion, also with a view to the application of new anti-tumor treatments, such as immunotherapy, aimed at OSCC patients.
format Online
Article
Text
id pubmed-10358763
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103587632023-07-21 A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans Rebaudi, Federico De Rosa, Alfredo Greppi, Marco Pistilli, Roberto Pucci, Resi Govoni, Flavio Andrea Iacoviello, Paolo Broccolo, Francesco Tomasello, Giuseppe Pesce, Silvia Laganà, Francesco Bianchi, Bernardo Di Gaudio, Francesca Rebaudi, Alberto Marcenaro, Emanuela Front Immunol Immunology INTRODUCTION: Oral squamous cell carcinoma (OSCC) accounts for approximately 90% of oral malignancies and has a 5-year mortality rate close to 50%. A consistent part (70%) of all oral cancers is diagnosed at an advanced stage since available screening techniques are ineffective. Therefore, it would be urgent to improve them. The diagnostic gold standard is tissue biopsy with histological and immunohistochemical assessment. This method presents some limitations. Biopsy is invasive and the histopathological evaluation is semi-quantitative, and the absolute abundance of the target cannot be reliably determined. In addition, tissue is highly processed and may lead to loss of information of the natural state. The search for classical and new clinical biomarkers on fragments of tissue/cells collected with a cytobrush is a highly hopeful technique for early detection and diagnosis of OSCC, because of its non-invasive sampling and easy collection method. METHODS: Here we analyzed cytobrush biopsies samples collected from the oral cavity of 15 patients with already diagnosed OSCC by applying an innovative high-sensitivity ELISA technique, in order to verify if this approach may provide useful information for detection, diagnosis, and prognosis of OSCC. To this end, we selected six biomarkers, already used in clinical practice for the diagnosis of OSCC (EGFR, Ki67, p53) or selected based on recent scientific and clinical data which indicate their presence or over-expression in cells undergoing transformation and their role as possible molecular targets in immunecheckpoints blockade therapies (PD-L1, HLA-E, B7-H6). RESULTS: The selected tumor biomarkers were highly expressed in the tumor core, while were virtually negative in healthy tissue collected from the same patients. These differences were highly statistically significant and consistent with those obtained using the gold standard test clearly indicating that the proposed approach, i.e. analysis of biomarkers by a custom ELISA technique, is strongly reliable. DISCUSSION: These preliminary data suggest that this non-invasive rapid phenotyping technique could be useful as a screening tool for phenotyping oral lesions and support clinical practice by precise indications on the characteristics of the lesion, also with a view to the application of new anti-tumor treatments, such as immunotherapy, aimed at OSCC patients. Frontiers Media S.A. 2023-07-06 /pmc/articles/PMC10358763/ /pubmed/37483588 http://dx.doi.org/10.3389/fimmu.2023.1216107 Text en Copyright © 2023 Rebaudi, De Rosa, Greppi, Pistilli, Pucci, Govoni, Iacoviello, Broccolo, Tomasello, Pesce, Laganà, Bianchi, Di Gaudio, Rebaudi and Marcenaro https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Rebaudi, Federico
De Rosa, Alfredo
Greppi, Marco
Pistilli, Roberto
Pucci, Resi
Govoni, Flavio Andrea
Iacoviello, Paolo
Broccolo, Francesco
Tomasello, Giuseppe
Pesce, Silvia
Laganà, Francesco
Bianchi, Bernardo
Di Gaudio, Francesca
Rebaudi, Alberto
Marcenaro, Emanuela
A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
title A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
title_full A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
title_fullStr A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
title_full_unstemmed A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
title_short A new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive ELISA immunoassay: a pilot study in humans
title_sort new method for oral cancer biomarkers detection with a non-invasive cyto-salivary sampling and rapid-highly sensitive elisa immunoassay: a pilot study in humans
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10358763/
https://www.ncbi.nlm.nih.gov/pubmed/37483588
http://dx.doi.org/10.3389/fimmu.2023.1216107
work_keys_str_mv AT rebaudifederico anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT derosaalfredo anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT greppimarco anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT pistilliroberto anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT pucciresi anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT govoniflavioandrea anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT iacoviellopaolo anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT broccolofrancesco anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT tomasellogiuseppe anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT pescesilvia anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT laganafrancesco anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT bianchibernardo anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT digaudiofrancesca anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT rebaudialberto anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT marcenaroemanuela anewmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT rebaudifederico newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT derosaalfredo newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT greppimarco newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT pistilliroberto newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT pucciresi newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT govoniflavioandrea newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT iacoviellopaolo newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT broccolofrancesco newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT tomasellogiuseppe newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT pescesilvia newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT laganafrancesco newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT bianchibernardo newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT digaudiofrancesca newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT rebaudialberto newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans
AT marcenaroemanuela newmethodfororalcancerbiomarkersdetectionwithanoninvasivecytosalivarysamplingandrapidhighlysensitiveelisaimmunoassayapilotstudyinhumans